OptimizeRx (NASDAQ:OPRX) Price Target Cut to $18.00 by Analysts at Roth Mkm

OptimizeRx (NASDAQ:OPRX) had its price target cut by Roth Mkm from $32.00 to $18.00 in a research note published on Friday,Benzinga reports. They currently have a buy rating on the stock.

OPRX has been the topic of a number of other research reports. Stifel Nicolaus reduced their price objective on OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday. B. Riley Financial reiterated a “buy” rating and issued a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research note on Friday. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.

OptimizeRx Trading Down 10.5%

Shares of OPRX stock traded down $0.79 during mid-day trading on Friday, reaching $6.74. The company’s stock had a trading volume of 2,099,710 shares, compared to its average volume of 437,141. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $125.63 million, a PE ratio of 25.92 and a beta of 1.20. The company’s 50 day simple moving average is $10.52 and its 200-day simple moving average is $14.73. OptimizeRx has a 12-month low of $3.99 and a 12-month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. On average, research analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its board has approved a stock buyback plan on Thursday, March 5th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Institutional Trading of OptimizeRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its holdings in OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after acquiring an additional 1,818 shares in the last quarter. Quantbot Technologies LP bought a new position in OptimizeRx during the 2nd quarter valued at $44,000. BNP Paribas Financial Markets grew its holdings in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in OptimizeRx during the 4th quarter worth $62,000. Finally, USA Financial Formulas bought a new stake in shares of OptimizeRx in the 3rd quarter worth about $131,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx News Summary

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.